Clinical trial
Phase II Trial of Nab-Paclitaxel as First Line Cytotoxic Chemotherapy in Patients With Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma
NCT02076243 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Trial of Nab-Paclitaxel as First Line Cytotoxic Chemotherapy in Patients With Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 31, 2014
- Completion date
- October 31, 2015
- Enrollment
- 2 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.